Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSP-2009 is a proprietary, next-generation psychedelic small molecule developed by Mindset Pharma, which was acquired by Otsuka Pharmaceutical in 2023. It acts as a 5-HT2A receptor agonist and is designed as an optimized psilocybin analog, specifically belonging to Mindset's 'Family 2' portfolio of compounds. These molecules are engineered to offer improved pharmacological properties, such as increased potency and a potentially shorter duration of effect compared to first-generation psychedelics like psilocybin. MSP-2009 is being developed for the treatment of psychiatric disorders, including treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), with the aim of providing a more predictable and scalable therapeutic option for patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MSP-2009.